Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Breast Cancer | Research

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

Authors: Xiuzhi Zhu, Li Chen, Binhao Huang, Xiaoguang Li, Liu Yang, Xin Hu, Yizhou Jiang, Zhimin Shao, Zhonghua Wang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC can be improved by combination with the CDK4/6 inhibitor (CDK4/6i) palbociclib.

Methods

We screened primary olaparib-sensitive and olaparib-resistant cell lines from existing BRCA^mut/TNBC cell lines and generated cells with acquired olaparib resistance by gradually increasing the concentration. The effects of the PARPi olaparib and the CDK4/6i palbociclib on BRCA^mut/TNBC cell lines were examined in both sensitive and resistant cells in vitro and in vivo. Pathway and gene alterations were assessed mechanistically and pharmacologically.

Results

We demonstrated for the first time that the combination of olaparib and palbociclib has synergistic effects against BRCA^mut/TNBC both in vitro and in vivo. In olaparib-sensitive MDA-MB-436 cells, the single agent olaparib significantly inhibited cell viability and affected cell growth due to severe DNA damage. In olaparib-resistant HCC1937 and SUM149 cells, single-agent olaparib was ineffective due to potential homologous recombination (HR) repair, and the combination of olaparib and palbociclib greatly inhibited HR during the G2 phase, increased DNA damage and inhibited tumour growth. Inadequate DNA damage caused by olaparib activated the Wnt signalling pathway and upregulated MYC. Further experiments indicated that the overexpression of β-catenin, especially its hyperphosphorylation at the Ser675 site, activated the Wnt signalling pathway and mediated olaparib resistance, which could be strongly inhibited by combined treatment with palbociclib.

Conclusions

Our data provide a rationale for clinical evaluation of the therapeutic synergy of the PARPi olaparib and CDK4/6i palbociclib in BRCA^mut/TNBCs with high Wnt signalling activation and high MYC expression that do not respond to PARPi monotherapy.

Available only for authorised users

Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50. https://doi.org/10.1016/S0140-6736(16)31891-8.CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Waks AG, Winer EP. Breast Cancer treatment: a review. JAMA. 2019;321(3):288–300. https://doi.org/10.1001/jama.2018.19323.CrossRefPubMed

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90. https://doi.org/10.1038/nrclinonc.2016.66.CrossRefPubMedPubMedCentral

Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–40. https://doi.org/10.1016/j.ccell.2019.02.001.CrossRefPubMed

Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, Verschraegen C, Stover DG, Kaklamani V, Wang ZH, Shao ZM. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: theFUTURE trial. Cell Res. 2021;31(2):178–86. https://doi.org/10.1038/s41422-020-0375-9. Epub 2020 Jul 27.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. https://doi.org/10.1038/nature03445.CrossRefPubMed

Francica P, Rottenberg S. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. Genome Med. 2018;10(1):101. https://doi.org/10.1186/s13073-018-0612-8.CrossRefPubMedPubMedCentral

Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134–47. https://doi.org/10.1158/1055-9965.EPI-11-0775.CrossRef

10.

Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254–8. https://doi.org/10.1245/s10434-013-3205-1.CrossRefPubMed

11.

Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA approval summary: Olaparib Monotherapy in patients with deleterious Germline BRCA-mutated advanced ovarian Cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257–61. https://doi.org/10.1158/1078-0432.CCR-15-0887.CrossRefPubMed

12.

Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:1700.CrossRef

13.

Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–8. https://doi.org/10.1126/science.aam7344.CrossRefPubMedPubMedCentral

14.

Mateo J, Lord CJ, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437–47. https://doi.org/10.1093/annonc/mdz192.CrossRefPubMedPubMedCentral

15.

O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30. https://doi.org/10.1038/nrclinonc.2016.26.CrossRefPubMed

16.

de Groot AF, Kuijpers CJ, Kroep JR. CDK4/6 inhibition in early and metastatic breast cancer: a review. Cancer Treat Rev. 2017;60:130–8. https://doi.org/10.1016/j.ctrv.2017.09.003.CrossRefPubMed

17.

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35. https://doi.org/10.1016/S1470-2045(14)71159-3.CrossRefPubMed

18.

Raphael J, Helou J, Pritchard KI, Naimark DM. Palbociclib in hormone receptor positive advanced breast cancer: a cost-utility analysis. Eur J Cancer. 2017;85:146–54. https://doi.org/10.1016/j.ejca.2017.08.018.CrossRefPubMed

19.

Kim ES. Abemaciclib: First Global Approval. Drugs. 2017;77(18):2063–70. https://doi.org/10.1007/s40265-017-0840-z.CrossRefPubMed

20.

Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast Cancer. Clin Cancer Res. 2017;23(18):5561–72. https://doi.org/10.1158/1078-0432.CCR-17-0369.CrossRefPubMedPubMedCentral

21.

Salvador-Barbero B, Alvarez-Fernandez M, Zapatero-Solana E, El BA, Menendez M, Lopez-Casas PP, et al. CDK4/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell. 2020;37(3):340–53. https://doi.org/10.1016/j.ccell.2020.01.007.CrossRefPubMed

22.

Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, et al. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. Ebiomedicine. 2019;43:225–37. https://doi.org/10.1016/j.ebiom.2019.03.027.CrossRefPubMedPubMedCentral

23.

Ashton JC. Drug combination studies and their synergy quantification using the Chou-Talalay method--letter. Cancer Res. 2015;75(11):2400. https://doi.org/10.1158/0008-5472.CAN-14-3763.CrossRefPubMed

24.

Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363–7. https://doi.org/10.1073/pnas.92.20.9363.CrossRefPubMedPubMedCentral

25.

Sun R, Xie HY, Qian JX, Huang YN, Yang F, Zhang FL, et al. FBXO22 possesses both Protumorigenic and Antimetastatic roles in breast Cancer progression. Cancer Res. 2018;78(18):5274–86. https://doi.org/10.1158/0008-5472.CAN-17-3647.CrossRefPubMed

26.

Liu HY, Liu YY, Yang F, Zhang L, Zhang FL, Hu X, et al. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 2020;48(7):3638–56. https://doi.org/10.1093/nar/gkaa130.CrossRefPubMedPubMedCentral

27.

Lu Q, Zhang FL, Lu DY, Shao ZM, Li DQ. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells. Cancer Med. 2019;8(15):6730–40. https://doi.org/10.1002/cam4.2528.CrossRefPubMedPubMedCentral

28.

Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999;13(20):2633–8. https://doi.org/10.1101/gad.13.20.2633.CrossRefPubMedPubMedCentral

29.

Guglielmi C, Cerri I, Evangelista M, Collavoli A, Tancredi M, Aretini P, et al. Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway. Breast Cancer Res Treat. 2013;141(3):515–22. https://doi.org/10.1007/s10549-013-2705-9.CrossRefPubMed

30.

Zheng YZ, Xue MZ, Shen HJ, Li XG, Ma D, Gong Y, et al. PHF5A epigenetically inhibits apoptosis to promote breast Cancer progression. Cancer Res. 2018;78(12):3190–206. https://doi.org/10.1158/0008-5472.CAN-17-3514.CrossRefPubMed

31.

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–308. https://doi.org/10.1038/nprot.2013.143.CrossRefPubMedPubMedCentral

32.

Jin X, Ge LP, Li DQ, Shao ZM, Di GH, Xu XE, et al. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer. Mol Cancer. 2020;19(1):87. https://doi.org/10.1186/s12943-020-01210-9.CrossRefPubMedPubMedCentral

33.

Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225. https://doi.org/10.1038/s41598-019-57094-3.CrossRefPubMedPubMedCentral

34.

Yang YL, Zhang Y, Li DD, Zhang FL, Liu HY, Liao XH, et al. RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2. Cell Death Differ. 2020;27(3):1105–18. https://doi.org/10.1038/s41418-019-0400-z.CrossRefPubMed

35.

Seluanov A, Mao Z, Gorbunova V. Analysis of DNA double-strand break (DSB) repair in mammalian cells. J Vis Exp. 2010;(43). https://doi.org/10.3791/2002.

36.

Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol. 2010;5(3):186–91. https://doi.org/10.2174/157488410791498824.CrossRefPubMed

37.

Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):688–95. https://doi.org/10.1038/nsmb.1831.CrossRefPubMedPubMedCentral

38.

McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012;11(14):2747–55. https://doi.org/10.4161/cc.21127.CrossRefPubMedPubMedCentral

39.

Scholz BA, Sumida N, de Lima C, Chachoua I, Martino M, Tzelepis I, et al. WNT signaling and AHCTF1 promote oncogenic MYC expression through super-enhancer-mediated gene gating. Nat Genet. 2019;51(12):1723–31. https://doi.org/10.1038/s41588-019-0535-3.CrossRefPubMed

40.

Wang Q, Zhou Y, Rychahou P, Harris JW, Zaytseva YY, Liu J, et al. Deptor is a novel target of Wnt/beta-catenin/c-Myc and contributes to colorectal Cancer cell growth. Cancer Res. 2018;78(12):3163–75. https://doi.org/10.1158/0008-5472.CAN-17-3107.CrossRefPubMedPubMedCentral

41.

Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008;133(2):340–53. https://doi.org/10.1016/j.cell.2008.01.052.CrossRefPubMedPubMedCentral

42.

Taurin S, Sandbo N, Yau DM, Sethakorn N, Dulin NO. Phosphorylation of beta-catenin by PKA promotes ATP-induced proliferation of vascular smooth muscle cells. Am J Physiol Cell Physiol. 2008;294(5):C1169–74. https://doi.org/10.1152/ajpcell.00096.2008.CrossRefPubMed

43.

Stamos JL, Weis WI. The β-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5:a7898.CrossRef

44.

Noordermeer SM, van Attikum H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29(10):820–34. https://doi.org/10.1016/j.tcb.2019.07.008.CrossRefPubMed

45.

Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for Talimogene Laherparepvec, a new Oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048–54. https://doi.org/10.1158/1078-0432.CCR-15-2667.CrossRefPubMed

46.

Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SD. Rad51 degradation: role in Oncolytic virus-poly (ADP-ribose) polymerase inhibitor combination therapy in Glioblastoma. J Natl Cancer Inst. 2017;109(3):1–13. https://doi.org/10.1093/jnci/djw229.CrossRefPubMed

47.

Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, et al. Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors. Cancer Res. 2019;79(3):452–60. https://doi.org/10.1158/0008-5472.CAN-18-2077.CrossRefPubMed

48.

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, et al. CDK12 inhibition reverses De novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast Cancer. Cell Rep. 2016;17(9):2367–81. https://doi.org/10.1016/j.celrep.2016.10.077.CrossRefPubMedPubMedCentral

49.

Tomimatsu N, Mukherjee B, Catherine HM, Ilcheva M, Vanessa CC, Louise HJ, et al. Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice. Nat Commun. 2014;5(1):3561. https://doi.org/10.1038/ncomms4561.CrossRefPubMed

50.

Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, et al. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019;10(1):2910. https://doi.org/10.1038/s41467-019-10993-5.CrossRefPubMedPubMedCentral

51.

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor Upregulates PD-L1 expression and enhances Cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–20. https://doi.org/10.1158/1078-0432.CCR-16-3215.CrossRefPubMedPubMedCentral

52.

Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79(2):311–9. https://doi.org/10.1158/0008-5472.CAN-18-1003.CrossRefPubMed

53.

Liszczak G, Diehl KL, Dann GP, Muir TW. Acetylation blocks DNA damage-induced chromatin ADP-ribosylation. Nat Chem Biol. 2018;14(9):837–40. https://doi.org/10.1038/s41589-018-0097-1.CrossRefPubMedPubMedCentral

54.

Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, et al. An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations. Clin Cancer Res. 2018;24(13):3163–75. https://doi.org/10.1158/1078-0432.CCR-18-0204.CrossRefPubMedPubMedCentral

55.

Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA Demethylating agents - a potential therapy for Cancer. Cancer Cell. 2016;30(4):637–50. https://doi.org/10.1016/j.ccell.2016.09.002.CrossRefPubMedPubMedCentral

56.

Wang H, Xiang D, Liu B, He A, Randle HJ, Zhang KX, et al. Inadequate DNA damage repair promotes mammary Transdifferentiation, leading to BRCA1 breast Cancer. Cell. 2019;178(1):135–51. https://doi.org/10.1016/j.cell.2019.06.002.CrossRefPubMedPubMedCentral

57.

Karimaian A, Majidinia M, Bannazadeh BH, Yousefi B. The crosstalk between Wnt/β-catenin signaling pathway with DNA damage response and oxidative stress: implications in cancer therapy. DNA Repair. 2017;51:14–9. https://doi.org/10.1016/j.dnarep.2017.01.003.CrossRefPubMed

58.

Prochownik EV, Li Y. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle. 2007;6(9):1024–9. https://doi.org/10.4161/cc.6.9.4161.CrossRefPubMed

59.

Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–90. https://doi.org/10.1038/nrc2231.CrossRefPubMed

60.

Wade M, Wahl GM. C-Myc, genome instability, and tumorigenesis: the devil is in the details. Curr Top Microbiol Immunol. 2006;302:169–203.PubMed

61.

Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–66. https://doi.org/10.1093/annonc/mdz012.CrossRefPubMedPubMedCentral

62.

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in advanced breast Cancer. N Engl J Med. 2016;375(20):1925–36. https://doi.org/10.1056/NEJMoa1607303.CrossRefPubMed

Title: Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
Authors: Xiuzhi Zhu
Li Chen
Binhao Huang
Xiaoguang Li
Liu Yang
Xin Hu
Yizhou Jiang
Zhimin Shao
Zhonghua Wang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01930-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Zinc transporter SLC39A13/ZIP13 facilitates the metastasis of human ovarian cancer cells via activating Src/FAK signaling pathway

Correction to: Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1

TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity

Neutrophil Extracellular Traps: A New Player in Cancer Metastasis and Therapeutic Target

Correction to: microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis

TRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination-dependent manner

Keynote webinar | Spotlight on antibody–drug conjugates in cancer